Yuzi Cai
Overview
Explore the profile of Yuzi Cai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
162
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ji Y, Xiao Y, Li S, Fan Y, Cai Y, Yang B, et al.
Ren Fail
. 2024 Jul;
46(2):2365982.
PMID: 39010816
This study aimed to explore the mechanism of Xiaoyu Xiezhuo decoction (XXD) on ischemia-reperfusion-induced acute kidney injury (IRI-AKI) using network pharmacology methods and gut microbiota analysis. A total of 1778...
2.
Zhou M, Zhang S, Bai X, Cai Y, Zhang Z, Zhang P, et al.
Eur J Pharmacol
. 2024 Jun;
978:176715.
PMID: 38852699
Renal fibrosis is the final pathological change of kidney disease, it has also been recognized to be critical for the final progression of diabetic nephropathy (DN) to kidney failure. Acteoside...
3.
Chen H, Guo J, Cai Y, Zhang C, Wei F, Sun H, et al.
J Ethnopharmacol
. 2023 Nov;
321:117481.
PMID: 38007164
Ethnopharmacological Relevance: Modified Da Chaihu decoction (MDCH) is a traditional Chinese herbal prescription that has been used in the clinic to treat type 2 diabetes (T2D). Previous studies have confirmed...
4.
Wang Y, Liu T, Cai Y, Liu W, Guo J
Front Endocrinol (Lausanne)
. 2023 Oct;
14:1244705.
PMID: 37876546
Diabetic nephropathy (DN) is a complication of diabetes mellitus (DM) and the main cause of excess mortality in patients with type 2 DM. The pathogenesis and progression of DN are...
5.
Jia Q, Guo J, Cai Y, Huang W, Zhu Z, Xia C, et al.
Evid Based Complement Alternat Med
. 2022 Oct;
2022:9730753.
PMID: 36248420
Introduction: IgA nephropathy (IgAN) is a common issue. In China, (AM) is widely used in the treatment of IgAN. However, their combined effectiveness and safety for this purpose have not...
6.
Luo Q, Cai Y, Zhao Q, Tian L, Liu Y, Liu W
Ren Fail
. 2022 Jul;
44(1):806-814.
PMID: 35856157
Background/objective: Diabetes mellitus is a common "non-gout" disease with high incidence. Several studies have shown that serum uric acid level in patients with diabetes is higher than that in healthy...
7.
Luo Q, Cai Y, Zhao Q, Jiang Y, Tian L, Liu Y, et al.
J Diabetes Res
. 2022 Jun;
2022:3770417.
PMID: 35746917
Diabetic nephropathy (DN)-chronic kidney damage caused by hyperglycemia-eventually develops into end-stage renal disease (ESRD). Melatonin is a powerful antioxidant that has a wide range of biological activities. Potentially helpful effects...
8.
Luo Q, Wei R, Cai Y, Zhao Q, Liu Y, Liu W
Front Med (Lausanne)
. 2022 Mar;
9:793203.
PMID: 35280867
Objective: To evaluate the effects of vitamin E, pioglitazone, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with non-alcoholic fatty liver disease (NAFLD). Design: A network...
9.
Cai Y, Feng Z, Jia Q, Guo J, Zhang P, Zhao Q, et al.
Front Pharmacol
. 2022 Feb;
12:801094.
PMID: 35222012
Hypertensive renal injury is a complication of hypertension. () is a traditional Chinese medicine used to treat chronic kidney diseases especially renal fibrosis. Autophagy is described as a cell self-renewal...
10.
Tian L, Cai Y, Zheng H, Ai S, Zhou M, Luo Q, et al.
Front Pharmacol
. 2021 Aug;
12:691878.
PMID: 34349651
We aimed to evaluate the efficacy of canagliflozin for the treatment of specific cardiovascular and renal outcomes in Type 2 diabetes mellitus (T2DM) patients by means of a systematic review...